An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Someone on an online forum asked for dosing advice because they’re about to try MOTS‑C to treat long COVID (LC) and reconstituted a 10 mg vial with 2 mL of bacteriostatic water. They want to know how much to inject and how often, because different sources give different numbers and nothing seems tailored to long COVID. MOTS‑C is a short peptide that was discovered inside mitochondria, the cell’s energy factories. In simple terms, it’s a tiny protein fragment that cells naturally make in small amounts. Early lab and animal studies suggest it can change how cells use energy and handle stress, and that has led some people to wonder if it could help conditions with tiredness, inflammation, or metabolic problems. But that doesn’t mean it’s a proven therapy for long COVID in people. What the evidence actually shows is limited. Most studies of MOTS‑C have been done in cells or in animals, or they involve only a few human participants in early-phase trials. There’s no large, reliable clinical trial showing MOTS‑C safely and effectively treats long COVID. Anecdotal reports and forum threads (like the one you quoted) offer many dosing schemes, but these are not medical guidance and reflect personal experiments rather than controlled studies. So we don’t have solid data on what dose, frequency, or treatment length works for long COVID, or how big any benefit might be. Why this matters is straightforward: if MOTS‑C ever is helpful, people with long COVID are an obvious group to study because fatigue, exercise intolerance, and metabolic changes are common in the condition. That’s why people are experimenting on their own. But until controlled trials are done, anyone considering this should be aware they’re entering uncertain territory. Doctors, researchers, and people living with long COVID would all benefit from well‑designed studies that test specific doses and measure meaningful outcomes. There are important caveats and risks. MOTS‑C is not an approved treatment for long COVID. Self-mixing peptides and injecting them carries infection and dosing risks if done without sterile technique and medical oversight. Potential side effects aren’t well characterized in humans, and interactions with other medications or underlying conditions are unknown. Pregnant or breastfeeding people, those with serious health issues, and anyone taking multiple drugs should be particularly cautious. Regulatory status varies by country; in many places, peptides sold online are unregulated and not pharmaceutical‑grade. If someone is considering this, the safest steps are to talk with a knowledgeable clinician, consider enrolling in a legitimate clinical trial if one exists, and avoid relying on forum dosing charts as medical advice. Bottom line: MOTS‑C is an interesting experimental peptide but there’s no reliable evidence yet to tell you a safe, effective dose for long COVID — proceed with caution and get medical guidance.
Source: r/Peptides